perceptive discovery

In Vivo Services

Translational Imaging and Preclinical Research Solutions Across Oncology, CNS, and Advanced Therapeutics



Perceptive Discovery delivers integrated in vivo imaging and translational research solutions that help drug developers generate decision-ready data from discovery through IND-enabling studies. Our teams combine advanced imaging, radiochemistry, animal models, and quantitative analysis to support oncology, CNS, and radiopharmaceutical programs.

Therapeutic Area Expertise

Oncology

- CDX, syngeneic & orthotopic models
- Biodistribution & efficacy studies
- RLT & combination therapy evaluation

CNS

- CNS biodistribution & target occupancy studies
- Neuropharmacodynamic imaging biomarkers
- Neuroinflammation & neurodegeneration models

ASO, AAV & neurogenetic therapeutic support

Additional Areas

- Fibrosis & inflammation
- Cardiovascular & metabolic disease
- Rare disease models

The Perceptive Discovery Advantage

Integrated Translational Workflows
Imaging, radiochemistry, and quantitative analysis in one partner.

Oncology & CNS Expertise
Deep experience across complex disease models and therapeutic modalities.

Advanced Quantitative Imaging
Longitudinal same-animal imaging for sensitive biodistribution and response assessment.

IND-Enabling Support
Regulatory-grade biodistribution and dosimetry studies supporting clinical translation.

Specialized Alpha Imaging
Quantitative imaging for alpha-emitting therapies including Pb-212, Ac-225 and At-211.

Advanced neuroimaging and quantitative biomarker workflows
Supporting CNS biodistribution, target engagement, occupancy, and pharmacodynamic assessment.

Study Capabilities

- Biodistribution
- PK/PD Assessment
- Efficacy Studies
- Target Engagement
- CNS Penetration & Dose Occupancy Studies
- Dosimetry
- IND-Enabling Studies
- Large Animal & NHP Studies

Preclinical Models Supported

Oncology

- CDX
- Syngeneic
- Orthotopic
- PDX

CNS

- Genetic
- Pharmacologically-induced
- Stereotaxic Surgically-induced
- Transection Surgically-induced
- Neuro-oncology

Selected CDX Models

Tumor Type	Models
Prostate	LNCaP, 22RV1
Colorectal	HCT116, Colo205, HT29
Lung	HCC827, H1975, A549
Glioblastoma	U87-MG
Pancreas	HPAF-II, MiaPaca-2

Additional models available upon request.

Imaging Modalities

Nuclear Imaging	Structural Imaging	Optical Imaging
PET	MRI	BLI
SPECT	CT / microCT	FLI
Alpha-SPECT™	Optoacoustic	CFT

Trusted Across Discovery Programs

3,000+
Preclinical Studies Supported

900+
Compound Radiolabeled

11,000+
Imaging Studies Completed

80+
IND Submission Supported

perceptive.com
hello@perceptive.com
©2026 Perceptive Discovery, LLC. All rights reserved

perceptive discovery